PQ 267
267. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer of a medication (details supplied); whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and when senior HSE management became directly involved in the reimbursement or commercial process; the current status of the process; and the objective factors which have informed the HSE's approach and decisions to date, without requiring disclosure of commercially confidential net pricing, in tabular form. [70807/26]
Introduced
7 October 2026
Last action
7 October 2026 · Medicinal Products
Status
written
Sponsors
David Cullinane
Subjects
Discovery layer
Source updated
7 October 2026
Summary
267. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer of a medication (details supplied); whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and when senior HSE management became directly involved in the reimbursement or commercial process; the current status of the process; and the objective factors which have informed the HSE's approach and decisions to date, without requiring disclosure of commercially confidential net pricing, in tabular form. [70807/26]
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
7 October 2026
Medicinal Products
267. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer of a medication (details supplied); whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and when senior HSE management became directly involved in the reimbursement or commercial process; the current status of the process; and the objective factors which have informed the HSE's approach and decisions to date, without requiring disclosure of commercially confidential net pricing, in tabular form. [70807/26]
Source: written
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Medicinal Products
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Medicinal Products
xml · EN · 7 October 2026
Question
text · EN · 7 October 2026
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- David Cullinane · Asking member
- Health · Health · Addressed to
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.oireachtas.ie/en/debates/question/2026-10-07/267/
- Open data entity: https://data.oireachtas.ie/ie/oireachtas/question/2026-10-07/pq_267
- ireland · q-2026-10-07-pq_267 · source updated 7 October 2026